1 rich Libsyn https://www.libsyn.com 300 600 Resistant hypertension remains one of the most stubborn challenges in cardiovascular medicine. &amp;nbsp; The Bax24 phase 3 trial, published in The Lancet (2026), evaluated baxdrostat, a selective aldosterone synthase inhibitor, in patients already receiving multiple antihypertensive agents. &amp;nbsp; Key findings: • −16.6 mmHg reduction in 24-hour ambulatory SBP • −14.0 mmHg placebo-corrected difference (p&amp;lt;0.0001) • 71% achieved BP control (&amp;lt;130 mmHg) vs 17% placebo • Acceptable safety profile, with hyperkalemia in 3% &amp;nbsp; These data highlight the growing importance of aldosterone dysregulation in resistant hypertension and suggest that targeted aldosterone synthase inhibition may represent a new therapeutic frontier. &amp;nbsp; Reference: Azizi M et al. Effect of Baxdrostat on Ambulatory Blood Pressure in Resistant Hypertension (Bax24). Lancet 2026. Dr. RR Baliga's 'Podkast for the Kurious Doc' http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40348495/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/199345375